Detailed narrative
AI Strategy and Customer Adoption
Veeva's AI strategy focuses on integrating AI solutions tightly with core systems, leveraging its trusted relationships and domain expertise. While customers are highly interested in AI for efficiency, they prioritize proven, scalable applications over speculative point solutions. Veeva aims to deliver quality, predictability, and regulatory compliance, ensuring its AI applications are durable and integrated within its platform, contrasting with the challenges customers face with custom builds or unproven startups.
The company views its relationship with large language model (LLM) providers as symbiotic, with LLMs serving as engines for Veeva's industry-specific AI applications.
Vault CRM Momentum and Transition
The Vault CRM platform continues to gain significant traction, with nearly 140 customers now live, exceeding previous estimates. The company has pulled forward📎 the end-of-support date for its legacy CRM from September 2030 to December 2029, reflecting confidence in Vault CRM's progress and the desire to avoid stragglers.
Veeva anticipates winning approximately 14 out of the top 20 pharma companies for Vault CRM, with remaining decisions expected to finalize in FY27. Management expressed high confidence in the firmness of these commitments, citing the proven stability and functionality of Vault CRM.
R&D Business Evolution
The R&D segment is experiencing a shift in growth drivers, moving from mature products like eTMF to newer, large-scale offerings such as RTSM, EDC, safety, and LIMS. This mix shift is influencing subscription growth rates, as these newer products are still early in their scaling phase.
Veeva recently secured a significant win with a top 20 pharma company standardizing on RTSM, highlighting the potential for enterprise-wide adoption of its specialized R&D solutions. The company sees a structural advantage in offering combined clinical operations and data management solutions.
Services and Customer Growth
Professional services, particularly business consulting and R&D implementation, saw strong execution in FY26 and are expected to continue growing profitably in FY27, supported by increased CRM migration activity. The company also noted an acceleration in customer count growth to 5%, attributed to strong execution in its 'basics' program targeting small and emerging biotechs.
This growth reflects the team's ability to execute well across different customer segments and product areas.
Long-Term Vision for AI in Life Sciences
Peter Gassner articulated a long-term vision for AI's transformative impact on life sciences, extending beyond mere efficiency gains to fundamentally improve patient outcomes. He emphasized that AI can bridge the gap between doctors and patients, addressing the 90% value loss in the current system by enabling more timely and correct treatments.
Veeva aims to play a crucial role in connecting the industry to its external ecosystem (clinical researchers, patients, doctors, regulators) through AI, leading to both societal benefits and revenue growth over the next 10-20 years. He believes the true bottleneck is patient access to the right treatment, not just drug discovery speed.
Study-by-Study Business Expansion
Veeva is increasing its focus on the study-by-study business through contract research organizations (CROs), aiming to OEM its technology for clinical trials. This represents a significant market opportunity, potentially reaching $1 billion, by offering products like EDC, RTSM, and eCOA through CROs.
This new go-to-market motion allows Veeva to participate in trials run by small biotechs who typically rely on CROs for technology and services, leveraging Veeva's scale and product excellence.